Tag Archives: CTXR stock research

Citius Pharmaceuticals (CTXR) posted a 25Q1 loss of $9.8 million or $1.30 per share.  I had projected a loss of $7.0 million or $0.93 per share.  Operating expenses, including R&D, G&A and (non-cash stock-based compensation, were greater than expected across … Continue reading →

Citius Pharmaceuticals (CTXR) posted a 24Q4 loss of $11.8 million or $1.64 per share.  Excluding an estimated $6 million milestone payment, which I had incorrectly expensed rather than capitalized, I had projected a $12.5 million or $1.73 per share loss.  … Continue reading →